Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination

Cancer Gene Therapy

Volumn 18, Issue 1, 2011, Pages 63-76

  Smith, K A ^a   Qiu, Z ^a   Wong, R ^a   Tam, V L ^a   Tam, B L ^b   Joea, D K ^a   Quach, A ^a   Liu, X ^a   Pold, M ^a   Malyankar, U M ^a   Bot, A ^a  

^a MannKind Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

co inhibitory receptors; DNA vaccines; lymph node targeted; melanoma; PD 1

Indexed keywords

DNA VACCINE; EPITOPE; MELAN A; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INGUINAL LYMPH NODE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; GENE EXPRESSION PROFILING; IMMUNIZATION, SECONDARY; LYMPH NODES; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA;

MURINAE;

EID: 78650306486     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.45     Document Type: Article

References (36)

1. Fecher LA, Flaherty KT. Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Canc Netw 2009; 7: 295-304.
2. Sullivan RJ, Atkins MB. Molecular-targeted therapy in malignant melanoma. Expert Rev Anticancer Ther 2009; 9: 567-581.
3. Cerottini JC, von Fliedner V, Boon T. Ann. Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches. Oncology 1992; 3: 11-16.
4. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
5. Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA. The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 1998; 21: 237-246.
6. Goodwin DP, Hornung MO, Krementz ET. Extraction and use of melanoma-associated protein for immunotherapy. Oncology 1973; 27: 258-265.
7. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR et al. Identification of the immuno-dominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-352. (Pubitemid 24181083)
8. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-495.
9. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-7130.
10. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233-240.
11. Rosenberg SA, Yang JC, Restifo NP. Cancer immuno-therapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
12. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. Clin Invest 2005; 115: 739-746.
13. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-270.
14. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-1918.
15. Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002; 168: 1717-1722.
16. Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncol 2007; 3: 299-306.
17. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
18. Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009; 15: 169-173.
19. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 2008; 13: 10-15.
20. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M et al. Phase 1 trial of intranodal injection of a Melan-A/ MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008; 31: 215-223.
21. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003; 98: 144-154.
22. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001; 98: 3299-3303.
23. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE et al. Central memory self/ tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102: 9571-9576.
24. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009; 106: 17469-17474.
25. Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004; 17: 370-389.
26. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8: 108-120.
27. Smith KA, Tam VL, Wong RM, Pagarigan RR, Meisenburg BL, Joea DK et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009; 27: 2603-2615.
28. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immuno-dominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154: 2257-2265.
29. b b2 m double knockout mice. J Exp Med 1997; 185: 2043-2051.
30. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK et al. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res 2009; 15: 6167-6176.
31. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-g and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304.
32. Huang B, Zhao J, Li H, He K-L, Chen Y, Mayer L et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-5014.
33. + T cell-associated PD-1 expression. Immunol Lett 2009; 127: 60-67.
34. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-182.
35. Ha SJ, West EE, Araki K, Smith KA, Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 2008; 223: 317-333.
36. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.